We use a few cookies

Essential cookies keep the library working. With your permission, we'd also like to use analytics to see what's useful and improve the experience. Read our Privacy Policy or Cookie Policy.

Skip to main content
Home/e-Resources/Medical Sciences/Stereotactic Ablative Body Radiotherapy for Oligoprogressive Estrogen Receptor–Positive Breast Cancer (TROG 20.03 AVATAR): A Phase II Prospective Multicenter Trial
PeriodicalsMedical Sciences

Stereotactic Ablative Body Radiotherapy for Oligoprogressive Estrogen Receptor–Positive Breast Cancer (TROG 20.03 AVATAR): A Phase II Prospective Multicenter Trial

Checking your access to this record.

Abstract & Overview

PURPOSE AVATAR (trial registration: ACTRN 12620001212943) is a multicenter phase II single-arm trial to evaluate whether stereotactic ablative body radiotherapy (SABR) for oligoprogressive estrogen receptor (ER)–positive human epidermal growth factor receptor 2 (HER2)–negative breast cancer can delay a change from combination cyclin-dependent kinase 4 and 6 inhibitor (CDK4/6i) and an aromatase inhibitor (AI) to next-line systemic therapy. METHODS Patients received SABR to all sites of oligoprogressive disease while continuing CDK 4/6i and AI therapy. SABR was permitted for further oligoprogression without altering systemic therapy. The primary end point was event-free survival defined as the time from SABR to either (1) a change in systemic therapy, (2) any progression within 6 months, or (3) the appearance of >3 new progressing lesions. A key secondary end point was modified progression-free survival (mPFS), defined as oligoprogression not amenable to further SABR, or death due to any cause. RESULTS Thirty-two eligible patients were recruited between August 2020 and November 2022, with a median follow-up of 24 months. The primary end point was met, with 47% (95% CI, 29 to 63) of patients remaining event-free for ≥6 months. The median mPFS was 9.9 months (95% CI, 4.1 to not reached), with an estimated 44% (95% CI, 26 to 60) and 36% (95% CI, 20 to 53) of patients maintaining systemic therapy unchanged for 12 and 24 months, respectively. Median PFS was 5.2 months (95% CI, 3.1 to 6.8), with 11 (34%) and two (6%) of patients receiving second and third courses of SABR, respectively. No grade 3 or higher toxicities were reported. CONCLUSION In patients with oligoprogressive ER-positive, HER2-negative breast cancer, these findings suggest that SABR is a viable strategy to maintain treatment with CDK 4/6i in lieu of a change in systemic therapy.

Cite this record

Steven David, E. M. Connolly, Mathias Bressel, Jennifer Pei-Ling Tan, Gerard G. Hanna, Reem Alomran, et al. (2025). Stereotactic Ablative Body Radiotherapy for Oligoprogressive Estrogen Receptor–Positive Breast Cancer (TROG 20.03 AVATAR): A Phase II Prospective Multicenter Trial. JCO oncology advances., (2). https://doi.org/10.1200/oa-25-00031

Copy in another style

David, S., Connolly, E. M., Bressel, M., Tan, J. P., Hanna, G. G., Alomran, R., Yip, E., Morton, C., Siva, S., & White, M. A. (2025). Stereotactic Ablative Body Radiotherapy for Oligoprogressive Estrogen Receptor–Positive Breast Cancer (TROG 20.03 AVATAR): A Phase II Prospective Multicenter Trial. JCO oncology advances.. https://doi.org/10.1200/oa-25-00031
Author names are used as deposited, so check their order before you submit.

Metadata is harvested from open-access indexes and can be incomplete. Check a citation against the published version before relying on it — see our open access & attribution policy.